secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-08-11T11:35:09+00:00
Accession:  0001193125-26-343446
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet posts Q2 2026 net loss of $14.0M; $257.6M cash funds operations through 2028
--------------------------------------------------------------------------------

- Q2 2026 net loss $14.0M vs $10.4M in Q2 2025; H1 2026 net loss $24.6M vs $28.6M.
- Cash, equivalents and marketable securities $257.6M as of June 30, 2026, expected to fund operations through 2028.
- Phase 3 trial of denifanstat in moderate to severe acne on track to initiate in U.S. in H2 2026.
- Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned before end of 2026.
- Completed $175.0M equity financing in April 2026; added to Russell 3000 and Russell 2000 indexes in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/0001193125-26-343446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer